Alkanolamines and Fatty Alkanolamides Group

These substances were identified for action under the Chemicals Management Plan (CMP). This screening assessment focuses on 11 substances referred to collectively as the Alkanolamines and Fatty Alkanolamides Group.

Summary of publications
Substance group Sub-group CAS RN Acronym DSL name Draft screening assessment Proposed conclusion on section 64 criteria Follow-up activities

Alkanolamines and Fatty Alkanolamides Group

1 141-43-5 MEA Ethanol, 2-amino- HTML Do not meet None planned at this time
1 100-37-8 DEEA Ethanol, 2-(diethylamino)-
1 142-78-9 LME Dodecanamide, N-(2-hydroxyethyl)-
2A 111-42-2 DEA Ethanol, 2,2'-iminobis- Under consideration
2A 120-40-1 LDE Dodecanamide, N,N-bis(2-hydroxyethyl)-
2A 68603-42-9Footnote a CDE Amides, coco, N,N-bis(hydroxyethyl)
2B 61791-31-9Footnote a CADEA Ethanol, 2,2'-iminobis-, N-coco alkyl derivs. None planned at this time
2B 61791-44-4Footnote a TADEA Ethanol, 2,2'-iminobis-, N-tallow alkyl derivs.
3 102-71-6 TEA Ethanol, 2,2',2''-nitrilotris- Under consideration
3 122-20-3Footnote b TIPA 2-Propanol, 1,1',1''-nitrilotris- None planned at this time
3 85204-21-3 Footnote a,Footnote c BATEA 2-Butenoic acid, 4-[(2-ethylhexyl)amino]-4-oxo-, (Z)-, compd. with 2,2',2''-nitrilotris[ethanol] (1:1)
Footnote a

This CAS RN is a UVCB (unknown or variable composition, complex reaction products, or biological materials).

Return to footnote a referrer

Footnote b

This substance was not identified under subsection 73(1) of the Canadian Environmental Protection Act, 1999 (CEPA 1999) but was included in this assessment as it was considered a priority on the basis of other human health concerns.

Return to footnote b referrer

Footnote c

This substance was not identified under subsection 73(1) of CEPA 1999 but was included in this assessment as it was considered a priority as a result of the approach described for identification of risk assessment priorities.

Return to footnote c referrer

Timelines
Date Activity
July 2021 Anticipated publication of the final screening assessment.
July 18, 2020 Publication and start of 60-day public comment period on the draft screening assessment (including follow-up activities for DEA, LDE, CDE and TEA). The related notice was published in the Canada Gazette, Part I: Vol. 154, No. 29.

Background

The 7 alkanolamine substances (CAS RNs 141-43-5, 100-37-8, 111-42-2, 61791-31-9, 61791-44-4, 102-71-6 and 122-20-3) in this screening assessment were originally referred to as the Alkanolamines Group under the CMP, while the 3 fatty alkanolamides (CAS RNs 120-40-1, 142-78-9, 68603-42-9) were moved to this group from the Fatty Amides Group as they potentially contain residual alkanolamines. One substance in this group, BATEA (CAS RN 85204-21-3), was included in this assessment because it was determined to be a priority as a result of the approach described for the identification of risk assessment priorities (IRAP).

Page details

Date modified: